HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leslie, W.D. Articles by Hobson, D. Search for Related Content PubMed PubMed Citation Articles by Leslie, W.D. Articles by Hobson, D.

Comparison of Iodine-123-Epidepride and Iodine-123-IBZM for Dopamine D2 Receptor Imaging

Departments of Nuclear Medicine, Human Genetics and Neurology University of Manitoba, Winnipeg, Canada

Correspondence: For correspondence or reprints contact: Dr. W.D. Leslie, Department of Internal Medicine (C5121), St. Boniface General Hospital, 409 Tache Ave., Winnipeg, Canada R2H 2A6.

ABSTRACT

Although ¹²³I-IBZM is widely used as a D2 receptor imaging agent, image quality is compromised by a relatively low target-to-nontarget ratio. Animal studies suggest that ¹²³I-epidepride (K_d 0.024 n/W) may be superior to ¹²³I-IBZM, but this agent has not been systematically studied in humans. Methods: We directly compared ¹²³I-epidepride and ¹²³I-IBZM in five normal volunteers (age range 30–58 yr, mean 43 yr). Brain SPECT imaging was performed 2 hr after the ¹²³I-IBZM injection (average dose 153 MBq). Iodine-123-epidepride scans were performed 1 hr (n = 3), 2 hr (n = 5) and 3 hr (n = 3) postinjection (average dose 149 MBq). Results: Both radiopharmaceuticals were well tolerated, Iodine-123-epidepride provided excellent visualization of the striatum. Percent specific striatum uptake at 2 hr (71.7 ± 4.9%) was much greater than with ¹²³I-IBZM (32.6 ± 5.3%, p < 0.01). Conclusion: Iodine-123-epidepride is a new D2 receptor agent that exhibits excellent neuroimaging properties and has a much higher affinity for striatal uptake than ¹²³I-IBZM.

Key Words: neuroimaging • neurotransmitter • dopamine

This article has been cited by other articles:

				W. W de Herder, A. E M Reijs, R. A Feelders, M. O van Aken, E. P Krenning, A.-J. van der Lely, and D. J Kwekkeboom Diagnostic imaging of dopamine receptors in pituitary adenomas Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S53 - S56. [Abstract] [Full Text] [PDF]

				B. E. Assmann, R. O. Robinson, R. A.H. Surtees, C. Brautigam, S. J.R. Heales, R. A. Wevers, J. Zschocke, K. Hyland, R. Sharma, and G. F. Hoffmann Infantile parkinsonism-dystonia and elevated dopamine metabolites in CSF Neurology, May 25, 2004; 62(10): 1872 - 1874. [Abstract] [Full Text] [PDF]

				D. Ferone, S. Lastoria, A. Colao, P. Varrella, G. Cerbone, W. Acampa, B. Merola, M. Salvatore, and G. Lombardi Correlation of Scintigraphic Results Using 123I-Methoxybenzamide with Hormone Levels and Tumor Size Response to Quinagolide in Patients with Pituitary Adenomas J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 248 - 252. [Abstract] [Full Text]